Fiche société
Eurofarma Laboratorios S.A.
Traitements, essais et publications liés.
Traitements4programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Flanax 550mgA phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). | Migraine | Phase 3 | À vérifier | Brazil | À vérifier |
| Maxalt 10Mg TabletA phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). | Migraine | Phase 3 | À vérifier | Brazil | À vérifier |
| Rizatriptan 10 mg + Naproxen 550mgA phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). | Migraine | Phase 3 | À vérifier | Brazil | À vérifier |
| Rizatriptan 10 mg + Naproxen 550mgA phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). | Migraine | Phase 3 | À vérifier | Brazil | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rizatriptan 10 mg + Naproxen 550mg | Migraine | Phase 3 | NCT04384367 | RELIEF — Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||